Local therapy for progressing spots in genitourinary cancers
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial explores whether treating only the new or growing spots of cancer (called oligoprogression) with local therapies like radiation or ablation can help you stay on your current systemic treatment longer. It is for people with prostate, bladder, or kidney cancer that has started to progress in a few places.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: prostate, bladder (urothelial), or kidney (renal cell).
- You are currently on a systemic treatment (like chemotherapy or immunotherapy) and can continue it, with a planned break of no more than 30 days to have local therapy.
- You have had at least one prior line of systemic therapy for metastatic disease that kept most of your cancer stable for 3 months or more.
- You have 5 or fewer new or growing spots of cancer (metastatic lesions) that can be safely treated with a local procedure (like radiation or ablation).
- You are 18 years or older and willing to follow all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if focusing treatment on a few new or growing lung tumors can help people with lung cancer who are already on systemic therapy. You may qualify if you have stable disease overall but a small number of new spots that can be safely treated with radiation or other local procedures.
This trial tests whether using local treatments (like targeted radiation or ablation) on a few new spots of cancer can help people whose cancer is otherwise stable on their current treatment. It enrolls people with various solid tumors, such as breast, gynecologic, head & neck, sarcoma, or other types.
This trial tests a cancer treatment that uses local therapies (like radiation or targeted heat) to destroy a small number of growing spots. It is for people with certain gastrointestinal cancers whose main treatment is working well except for a few new spots, so they can avoid switching to a different drug right away.
This study tests whether continuing your current systemic (whole-body) therapy is safe and helpful when only 1–2 metastatic spots start growing. It also checks whether adding local treatment (such as radiation or ablation) to those spots can better control the cancer.
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
This trial tests whether giving focused radiation to limited areas of cancer growth (up to 3 spots) can help control the disease in men with castration-resistant prostate cancer. You may be eligible if your cancer is growing slowly and you are already on hormone therapy.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.